Cerevance Secures $47M to Drive Innovation in CNS Therapeutics
April 25, 2024, 9:33 pm
Location: United States, Massachusetts, Boston
Employees: 51-200
Founded date: 2016
Total raised: $189.5M
Cerevance, a Boston-based company specializing in precision treatments for central nervous system (CNS) disorders, recently closed a $47 million Series B-1 Extension financing round. The funding, led by Agent Capital, Bioluminescence Ventures, and Double Point Ventures, will propel the development of novel therapies for conditions like Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, and frontotemporal dementia.
With the support of new investors MQB Partners and LifeRock Ventures, as well as existing backers Gates Frontier, GV, and Lightstone Ventures, Cerevance is set to advance its Phase 3 clinical trial for CVN424. This groundbreaking therapy, a non-dopamine treatment for Parkinson's disease, shows promise in addressing motor fluctuations and improving non-motor symptoms without the side effects associated with current medications.
Under the leadership of CEO Craig Thompson, Cerevance is leveraging its innovative approach to target discovery through the NETSseq platform. This technology identifies unique proteins specific to diseased brain circuits, paving the way for the development of highly specific treatments for CNS disorders.
The addition of Campbell Murray, MD, MPP, MBA, and Kouki Harasaki, Ph.D., MBA, to the Cerevance Board of Directors further strengthens the company's commitment to revolutionizing CNS drug discovery. By focusing on precision therapies and advancing a robust pipeline of clinical and preclinical programs, Cerevance aims to transform the lives of patients affected by debilitating CNS conditions.
As Cerevance continues to push the boundaries of innovation in CNS therapeutics, the company's dedication to precision, efficacy, and patient outcomes remains unwavering. With a strong team of scientists and drug developers driving progress, Cerevance is poised to make a significant impact in the field of neurology and bring hope to those in need of advanced treatments.
With the support of new investors MQB Partners and LifeRock Ventures, as well as existing backers Gates Frontier, GV, and Lightstone Ventures, Cerevance is set to advance its Phase 3 clinical trial for CVN424. This groundbreaking therapy, a non-dopamine treatment for Parkinson's disease, shows promise in addressing motor fluctuations and improving non-motor symptoms without the side effects associated with current medications.
Under the leadership of CEO Craig Thompson, Cerevance is leveraging its innovative approach to target discovery through the NETSseq platform. This technology identifies unique proteins specific to diseased brain circuits, paving the way for the development of highly specific treatments for CNS disorders.
The addition of Campbell Murray, MD, MPP, MBA, and Kouki Harasaki, Ph.D., MBA, to the Cerevance Board of Directors further strengthens the company's commitment to revolutionizing CNS drug discovery. By focusing on precision therapies and advancing a robust pipeline of clinical and preclinical programs, Cerevance aims to transform the lives of patients affected by debilitating CNS conditions.
As Cerevance continues to push the boundaries of innovation in CNS therapeutics, the company's dedication to precision, efficacy, and patient outcomes remains unwavering. With a strong team of scientists and drug developers driving progress, Cerevance is poised to make a significant impact in the field of neurology and bring hope to those in need of advanced treatments.